发明名称 METHODS FOR PREDICTING RESPONSE TO HDACI/DNMTI COMBINATION IN MULTIPLE MYELOMA
摘要 The present invention relates to a method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitors (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating the HADMS score trough the following formula (I) wherein βi represent the regression β coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi) iv) comparing the score HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patient will respond to the combination treatment when the HADMS score is higher than the predetermined reference value HADMSR or concluding that the patient will not respond to the combination treatment when the HADMS score is lower than the predetermined reference value HADMSR.;HADMS=∑i=1nβi×Ci(I)
申请公布号 US2017096710(A1) 申请公布日期 2017.04.06
申请号 US201515127803 申请日期 2015.03.20
申请人 INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE) ;UNIVERSITE DE MONTPELLIER ;CENTRE HOSPITALIER UNIVERSITAIRE DE MONTPELLIER 发明人 MOREAUX Jérôme;KLEIN Bernard
分类号 C12Q1/68;G06F19/00;G06F19/24;A61K31/706;A61K31/167 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method of testing whether a patient suffering from multiple myeloma will respond or not to a combination treatment consisting of at least one histone deacetylase inhibitor (HDACi) with at least one DNA methyltransferase inhibitor (DNMTi) comprising: i) determining the expression level (ELi) of several genes G1-Gn selected from table A in a biological sample obtained from said patient ii) comparing the expression level (ELi) determined at step i) with a predetermined reference level (ELRi) iii) calculating a histone acetylation/DNA methylation score (HADMS) through the following formulaHADMS=∑i=1nβi×Ci wherein βi represent the regression β coefficient reference value for the gene Gi and Ci=1 if the expression of the gene Gi (ELi) is higher than the predetermined reference level (ELRi) or Ci=−1 if the expression of the gene (ELi) is lower than or equal to the predetermined reference level (ELRi), iv) comparing the HADMS determined at step iii) with a predetermined reference value HADMSR v) and concluding that the patient will respond to the combination treatment when the HADMS is higher than the predetermined reference value HADMSR or concluding that the patient will not respond to the combination treatment when the HADMS is lower than the predetermined reference value HADMSR.
地址 Paris FR